Endpoints Exclusive: Startup aims to tackle “undruggable” neuro targets with tech from Kevan Shokat’s UCSF lab
July 30, 2024 | San Francisco, CA
This Endpoints News article explores the creation of Montara Therapeutics by Kevan Shokat and Nicholas Hertz after selling their first neuro startup to AbbVie. Learn more about the founding pair and their BrainOnly™ platform, along with a look at the research, the competitive landscape, and more of the team behind Montara.
Access the full article on the Endpoints News website.
Download